

RUTGERS
Ernest Mario School
of Pharmacy

Electronic Nicotine Delivery Systems (ENDS): Impact of recent FDA regulations

By Lam D. Ho, Pauline R. Mock, Nikitha R. Pathuri, Shivani A. Vudya,
Michael Tascam, Pharm.D., and Joseph A. Barone, Pharm.D., FCCP
 *Rutgers, The State University of New Jersey - New Brunswick
Ernest Mario School of Pharmacy*



214 **RUTGERS**
Ernest Mario School
of Pharmacy

Discussion (continued)

Future Implications
The findings of this study will be used to inform the development of future ENDS products that address the needs of the population that is most at risk for nicotine addiction. The study will also be used to inform the development of future ENDS products that address the needs of the population that is most at risk for nicotine addiction.

Limitations
The study was limited by the use of a cross-sectional design. The study was also limited by the use of a self-reported measure of nicotine use. The study was also limited by the use of a self-reported measure of nicotine use.

Conclusions
The study found that the use of ENDS is associated with a higher risk of nicotine addiction. The study also found that the use of ENDS is associated with a higher risk of nicotine addiction.

References

Background

Recent changes in the electronic cigarette market by the U.S. Food and Drug Administration (FDA) have resulted in a significant increase in the number of ENDS products available to consumers. This study was conducted to assess the impact of these changes on the use of ENDS products.

Objective

The objective of this study was to assess the impact of recent changes in the electronic cigarette market on the use of ENDS products.

Methods

This study was a cross-sectional study that used data from the National Health and Medical Research Council (NH&MRC) Australian Smoking and Alcohol Drinking Survey (ASADS).

Results (continued)

- 2016: Launch of the ENDS 1.0 product.
- 2017: ENDS 1.0 product.
- July 26, 2017: FDA guidance.
- April 24, 2018: FDA guidance.
- April 24, 2018: FDA guidance.
- April 24, 2018: FDA guidance.
- April 24, 2018: FDA guidance.

Limitations

Limiting nicotine use in adolescents will take time, as it depends on the decision to quit. Even when the authors take the ENDS and other ENDS products, it remains unclear whether they will reduce the level of cigarette nicotine use.

Conclusions

Limiting nicotine use in adolescents will take time, as it depends on the decision to quit. Even when the authors take the ENDS and other ENDS products, it remains unclear whether they will reduce the level of cigarette nicotine use.

Background

Recent changes in the electronic cigarette market by the U.S. Food and Drug Administration (FDA) have resulted in a significant increase in the number of ENDS products available to consumers. This study was conducted to assess the impact of these changes on the use of ENDS products.

Objective

The objective of this study was to assess the impact of recent changes in the electronic cigarette market on the use of ENDS products.

Methods

This study was a cross-sectional study that used data from the National Health and Medical Research Council (NH&MRC) Australian Smoking and Alcohol Drinking Survey (ASADS).

Results


This study was a cross-sectional study that used data from the National Health and Medical Research Council (NH&MRC) Australian Smoking and Alcohol Drinking Survey (ASADS).

Conclusions

This study was a cross-sectional study that used data from the National Health and Medical Research Council (NH&MRC) Australian Smoking and Alcohol Drinking Survey (ASADS).

References

This study was a cross-sectional study that used data from the National Health and Medical Research Council (NH&MRC) Australian Smoking and Alcohol Drinking Survey (ASADS).



152

RUTGERS Epinephrine auto-injectors: A case for a prescription-to-over-the-counter switch
Ernest M. ... Kostyan Valtchev, PharmD; Magge N. Gendli, PharmD, RPh; Alicia Swadek, PharmD Candidate; Joseph A. Barone, PharmD, FCCP; Michael Toscani, PharmD
Rutgers Institute for Pharmaceutical Safety, Rutgers School of Pharmacy, Rutgers University, Piscataway, NJ

Results

Proposed Drug Facts
Indication and Usage
Warnings and Precautions
Contraindications
Adverse Reactions
Interactions
Use in Specific Populations
How Supplied
How to Use
Storage and Stability
Other Information

Discussion

The RPL is the consumer's guide to self-administration of medication therapy at the point-of-care. The proposed RPL for the EpiPen, and its associated go through regulatory review, with the intent of the RPL, the label and associated insert coverage label, and associated educational materials, and other materials that will include comprehensive information that consumers may experience with the following Proposed Drug Facts section with patients, as follows:

Conclusions

Between working committees across issues that are difficult in the drug industry, the market, such as patients' safety and the absence of actual manufacturing. These are factors in the path to approval, as well as the ability to provide a solution.

151

